Join the Oncology Brothers as they work with expert Alexander Spira, MD, PhD, FACP, in reviewing key updates from ESMO 2023 centered on the management of lung cancer.
EP. 1: Updates from PAPILLON: 1L Amivantamab + Chemotherapy in Advanced NSCLC
Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Alexander Spira, MD, PhD, FACP, to review data from PAPILLON, which combined amivantamab and chemotherapy as frontline treatment for patients with advanced NSCLC.
EP. 2: Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: Results from MARIPOSA
Expert insight into results from MARIPOSA, a study of frontline amivantamab plus lazertinib in advanced non–small cell lung cancer, and the potential for this regimen’s use in real-world practice.
EP. 3: MARIPOSA-2: Amivantamab + Lazertinib + Chemotherapy in EGFR-Mutated Advanced NSCLC
Shared insight from key opinion leaders on results from MARIPOSA-2 and the role of amivantamab plus lazertinib and chemotherapy in patients with advanced NSCLC following progression on osimertinib.
EP. 4: LIBRETTO-431: 1L Selpercatinib in RET Fusion–Positive Advanced NSCLC
Alexander Spira, MD, PhD, FACP, joins the Oncology Brothers in reviewing data from LIBRETTO-431 and frontline selpercatinib in patients with RET fusion–positive advanced non–small cell lung cancer.
EP. 5: Key Takeaways: Trial Data in NSCLC from ESMO 2023
Following their program with expert Alexander Spira, MD, PhD, FACP, Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, share key takeaways from ESMO 2023 centered on advancements in the management of NSCLC.
2 Clarke Drive Cranbury, NJ 08512